**Biogen Breaks Ground on New Headquarters in Cambridge’s Kendall Common**
Biogen has officially broken ground on what will become its new global headquarters, marking the first private development within MIT’s three-million-square-foot Kendall Common in Cambridge, Massachusetts. The new headquarters, located at 75 Broadway, will consolidate the biotechnology company’s currently dispersed local operations into a single 580,000-square-foot, 16-story building.
“Helping to ensure that Biogen stays in Cambridge was very important to us,” said Patrick Rowe, Senior Vice President in MIT’s real estate group. “The company’s nearly 50-year history is a foundational component of the Kendall Square innovation ecosystem.”
The new facility is slated for completion in 2028, aligning with Biogen’s 50th anniversary.
The Kendall Common master plan, spanning 10 acres, will ultimately include eight buildings serving a mix of residential, office, laboratory, retail, and community purposes. This expansive development follows a decade-long review process and a federal agreement, and recently saw the opening of the John A. Volpe National Transportation Systems Center, constructed by MIT.
In related industry events, Connect Healthcare Real Estate 2025 will explore key issues in the sector—from capital markets and investment trends to development activity, leasing strategies, and the evolving needs of healthcare providers. Taking place October 14–15, 2025, in Irvine, the event promises insights into how demographic and economic trends are shaping tomorrow’s opportunities in healthcare real estate.
